Squarepoint
LYRA

Squarepoint’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Squarepoint’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-306
Closed -$1.93K – 4820
2025
Q1 		$1.93K Buy
+306
New +$2.86K ﹤0.01% 4472
2024
Q2 		– Sell
-233
Closed -$72.6K – 4413
2024
Q1 		$72.6K Buy
+233
New +$62.1K ﹤0.01% 3838
2023
Q2 		– Sell
-226
Closed -$23.4K – 3825
2023
Q1 		$23.4K Buy
+226
New +$28K ﹤0.01% 3118

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint's LYRA Position: Q2 2025 in Review

Squarepoint sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2025, closing a stake of 306 shares — an estimated $1.93K sold.

Squarepoint first reported a position in LYRA in Q1 2023 and held it in 3 quarters. The position peaked at $72.6K in Q1 2024. 30 funds tracked by Wall St. Rank hold LYRA as of Q2 2025.

  • Squarepoint reported no remaining LYRA THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • Squarepoint sold 306 LYRA THERAPEUTICS INC shares in Q2 2025, an estimated $1.93K.
  • Squarepoint first reported a position in LYRA THERAPEUTICS INC in Q1 2023 and held it in 3 quarters.
  • Squarepoint's LYRA THERAPEUTICS INC position peaked at $72.6K in Q1 2024.
  • 30 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.